Genenta’s series C marks start of Qianzhan’s European push

In the latest show of support for European biotech by Chinese investors, Genenta raised €13.2 million in a series C round that marks the first investment in the region by Shanghai’s Qianzhan Investment Management.

Qianzhan and Fidim, the office of the Rovati family, led the round, with two more new investors, the offices

Read the full 536 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE